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ABSTRACT 
 
Objectives: The aims were to analyze changes in nutritional parameters from diagnosis of 
ALS to death and to assess their relationships with survival at the time of diagnosis and 
during follow-up.  
Methods: Ninety-two ALS patients were included and clinically assessed every three months 
(ALS FRS, MMT, forced vital capacity, weight, BMI, percent weight loss). Bioimpedance 
was performed to evaluate body composition (fat-free mass, fat mass and hydration status) 
and phase angle. Survival analyses were performed from diagnosis to death or censoring date 
using a Cox model. 
Results: The evolution of nutritional parameters in ALS patients was marked by significant 
decreases in weight, BMI, fat-free mass and phase angle, and increased fat mass. We 
identified an adjusted 30% increased risk of death for a 5% decrease from usual weight at 
time of diagnosis (Relative Risk (RR): 1.30 95%CI 1.08-1.56). During follow-up, we 
identified adjusted 34% (95%CI 18-51) and 24% (95%CI 13-36) increased risks of death 
associated with each 5% decrease in usual weight and each unit decrease in usual BMI, 
respectively (p<0.0001). Malnutrition during the course was related to shorter survival 
(p=0.01), and fat mass level was associated with a better outcome (RR 0.90 for each 2.5-kg 
fat mass increment). 
Conclusions: Nutritional parameters of ALS patients worsened during evolution of the 
disease and worse nutritional status (at time of diagnosis or during the course) was associated 
with higher mortality. This study offers some justification for studying the use of therapeutic 
nutritional intervention to modify the survival of ALS patients. 
 3 
INTRODUCTION 
Alteration of nutritional status among patients suffering from amyotrophic lateral sclerosis 
(ALS) is multifactorial  involving: dysphagia, chewing difficulties, difficulty moving the 
extremities, reduced caloric intake (1) and hypermetabolism (2, 3). 
Malnutrition is an independent prognostic factor for survival during the course of ALS, with 
an eight-fold increased risk of death (4). Body mass index (BMI) has been identified as a 
prognostic factor for survival at time of gastrostomy placement (5) and indications for non-
invasive ventilation (6), and a recent study identified longer survival in ALS patients with a 
high blood LDL/HDL cholesterol level (7). 
To date, studies on relationships between nutritional status and survival of ALS patients have 
considered nutritional status only during the course of the disease. There is a need to obtain 
further information on the relationships between survival and nutritional status at the time of 
diagnosis. It would also be of great interest to evaluate this relationship during follow-up, and 
to describe the evolution of nutritional parameters during the course of the disease. The aims 
of this study were to collect the following data at the time of diagnosis and during subsequent 
follow-up, to analyze changes that occur and to assess their relationships with survival: 
anthropometric nutritional parameters (percentage of weight lost, BMI, triceps skinfold 
thickness representing fat mass, mid-arm muscular circumference representing fat-free mass) 
and paraclinical parameters (fat mass, fat-free mass, phase angle, extracellular/intracellular 
fluid volumes measured by total body impedance analysis (BIA)). 
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METHODS 
 
Eligibility criteria 
This study was performed within the Limoges ALS expert centre. A total of 92 ALS patients 
diagnosed between 1997 and 2007 according to Airlie House criteria were enrolled. They 
included patients with a definite, probable or probable laboratory-supported form either at 
time of diagnosis or during follow-up. Subjects had to be followed at least twice during the 
course by the nutritional unit of the centre, with the first nutritional evaluation performed at 
the time of diagnosis. 
Data collection 
Socio-demographic and neurological data were extracted from the computerized database of 
the ALS centre, which contains prospectively gathered clinical data on all ALS patients. The 
database was approved by the CNIL (Commission nationale de l’informatique et des Libertés) 
and patients gave their informed consent for data collection. End of data collection was March 
1st 2009. Clinical assessments were performed every 3 months.  
Neurological and respiratory assessments 
These consisted of manual muscular testing (MMT) of all extremities and neck, as defined by 
the Medical Research Council (maximal value 150) and the ALS Functional Rating Scale 
(ALS FRS), (maximal value 40). The neurologist specified the date of onset of the first 
disease symptom, and the site of onset (bulbar or spinal). Diagnosis delay was calculated as 
the time between the dates of first symptoms and of diagnosis. Forced respiratory vital 
capacity was measured using a Hans Rudolph pneumotachograph, integrated in a body 
plethysmography system 1085 (CPF Medical Graphics, St Paul, MN, USA). Results were 
expressed in relation to a theoretical calculated index value. 
Nutritional assessment 
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Patients were weighed in their underwear in a seated position on an electronic SECA chair 
scale (Vogel & Halke, Hamburg, Germany) recording to 0.1 kg. Height was obtained standing 
upright for all the patients at the first evaluation, using a SECA gauge recording to 0.2 cm 
(Vogel & Halke, Hamburg, Germany). BMI was calculated according to the formula 
BMI=weight/height2. Patients were classified for nutritional status using BMI as follows: (i) 
malnutrition: BMI <18.5 if age <70 years and BMI<21 if age ≥70 years; (ii) normal status: 
18.5≤BMI<25 if age <70 years and 21≤BMI<27 if age ≥70 years; (iii) overweight: 
25≤BMI<30 if age <70 years and 27≤BMI<30 if age ≥70 years; (iv) obesity: BMI≥30 (8, 9). 
Percentage of weight lost was calculated as compared to usual weight as recorded 6 months 
before the first symptoms. Units of BMI lost were accordingly calculated using usual weight. 
Triceps skinfold thickness (mm) was measured using a Harpenden caliper. Three 
measurements were performed on each side of the body, and the retained value was the mean 
of all. Mid-arm muscular circumference (MAMC, cm), was calculated using triceps skinfold 
thickness (TSF) and the mean mid-arm circumference (MAC, cm) measured on each side of 
the body, using the equation: MAMC=MAC-0.314xTSF (10). BIA was performed using an 
Analycor3 instrument with surface electrodes (Spengler, Paris, France) according to standard 
methods, at 50 kHz, 5 kHz and 100 kHz (11), (median number of evaluations: 3, interquartile 
range (IQR): 2-4). Monofrequency BIA measured phase angle (in degrees) which is directly 
related to cell membranes (amount and functional status of cells) and whose normal value is 
considered to be 6° and over in healthy subjects (12), fat mass (kg) and fat-free mass (kg), and 
bifrequency estimated extracellular and intracellular fluid volumes (in liters) and their ratio 
which gives a picture of the cell membrane status (12). Phase angle (PA) was obtained using 
the formula: PA=arctan(Xc/R) (in degrees), where Xc is the body reactance (resistive effect 
due to capacities induced by tissue interfaces and cell membrane in ohms) and R is the 
bioelectrical resistance (linked to bodily extracellular hydration, in ohms). 
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Power assessment 
When the total number of events is 74, a 0.050 level two-sided log-rank test for equality of 
survival curves will have 80% power to detect the difference between a group 1 survival 
probability at time t (24 months, for example) of 0.40, and a group 2 survival probability at 
time t of 0.62 (constant hazard ratio of 1.92). 
 
Statistical analysis 
Quantitative variables were described using median and IQR. Qualitative variables were 
described using frequency and percentage. Normality for distribution of quantitative variables 
was assessed using the Shapiro-Wilk test. Paired quantitative variables were compared using 
the Wilcoxon rank signed test. Quantitative variables were compared between groups using 
the Kruskal-Wallis test and pairwise comparisons used the Wilcoxon test. Paired proportions 
were compared using the Mac Nemar Chi-square test. Evolution of nutritional markers was 
plotted against time, using time until death as baseline. Means (+/- 1 standard deviation) are 
depicted on the graphs. We calculated means (+/- standard deviation) of nutritional markers 
for all patients at two common time points: time of death and time of diagnosis. At 
intermediate time points (at least 6 months, 12 months, and 18 months before death) the 
numbers of patients may be lower than the total due to death over time. Survival was analysed 
from date of diagnosis until the death of the patient or the censoring date - the date of last 
neurological consultation. The Kaplan–Meier method was used to estimate survival function 
and the log rank test was used to compare survival distribution among groups. Univariate and 
multivariate analyses were performed using the Cox proportional hazard model. To identify 
the prognostic value of nutritional variables measured at diagnosis, we adjusted our analyses 
acording to clinical markers measured at diagnosis: ALS FRS (five-unit increment), MMT 
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(five-unit increment), Airlie House Criteria (definite, probable, probable laboratory-supported 
ALS vs possible ALS), FVC (≥80% of theoretical value vs <80%) and diagnostic delay (1-
month increment). To identify the prognostic value of nutritional variables measured over the 
entire follow-up we used time-varying covariates for nutritional variables and for other 
neurological or respiratory adjustment variables: ALS FRS (five-unit increment), MMT (five-
unit increment), Airlie House criteria (definite ALS vs other categories) and FVC (10% 
increment) and diagnostic delay (1-month increment). Those adjustment variables were forced 
in the first multivariable model, which was simplified using a backward stepwise procedure. 
Survival analyses for nutritional variables were performed separately. Relevant interactions 
between variables in each final multivariate model were tested. Respect for hypotheses of 
loglinearities effects of quantitatives variables were checked graphically and hypotheses for 
proportional hazard were tested using an interaction term between time and variables. P 
value<0.05 was considered statistically significant. We complied with STROBE guidelines 
(13). Analyses were performed using SAS®, Version 9.1.2 (SAS Institute, Cary, NC). 
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RESULTS 
Baseline demographic and clinical characteristics 
Median age at diagnosis was 65.6 years (IQR 56.5-73.3) and the sex ratio was 1. Bulbar form 
at onset represented 48% of cases. Supplementary baseline clinical characteristics are 
depicted in Table e-1 (supplementary file). The median weight variation at diagnosis 
according to usual weight was -2.32% (IQR -7.76-0.68) and median BMI variation at 
diagnosis according to usual BMI was -0.55 unit (IQR -1.99-0.15) (Table e-2, supplementary 
file). The two latter values were significantly different from 0 (p=0.0001). At the time of 
diagnosis, 8.70% of patients were malnourished according to BMI category. 
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Supplementary file : Table e-1: Demographic, neurological and respiratory characteristics of ALS patients at time of diagnosis 
Characteristics 
Median or 
frequencies 
IQR or % N 
Age at diagnosis, years 65.64 (56.46-73.35) 92 
Gender Male/female 46/46 (50.00/50.00) 92 
Diagnosis delay, months 7.93 (6.05-12.22) 92 
Form at onset Bulbar/Spinal 44/48 (47.83/52.17) 92 
Airlie House criteria at diagnosis   92 
Definite 8 8.70  
Probable 53 57.61  
Probable laboratory-supported 3 3.26  
Possible 28 30.43  
ALS FRS score at diagnosis /40 33 (30-36) 92 
MMT score at diagnosis /150 135 (125-145) 92 
FVC (percent of theoretical value) 92 (73-108) 92 
Legend: IQR: Interquartile range; ALS FRS: Amyotrophic Lateral Sclerosis Functional Rating Score; MMT: manual muscular testing; FVC : 
forced vital capacity. 
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Supplementary file : Table e-2: Nutritional variables at time of diagnosis 
 
 
Legend: IQR: Interquartile range. BMI categorization: (i) Malnutrition: BMI <18.5 if age <70 years 
and BMI<21 if age ≥70 years; (ii) Normal status 18.5≤BMI<25 if age <70 years and 21≤BMI<27 if 
Nutritional variables 
Median or 
frequencies 
IQR or % N 
Weight, kg 66.15 (56.95-75.00) 92 
Body mass index 24.17 (21.63-26.91) 92 
Rate of weight loss from usual weight (% / month) -0.32  (-1.04-0.08) 92 
Rate of BMI loss from usual BMI (unit / month) -0.08 (-0.25-0.02) 92 
BMI categories*   92 
 Malnourished 8 8.70  
 Normal 50 54.30  
 Overweight 23 25.00  
 Obese 11 12.00  
Weight variation from usual weight (%) -2.32* (-7.76-0.68) 92 
BMI variation from usual BMI (unit) -0.55* (-1.99-0.15) 92 
Mid-arm muscle circumference, cm 23.89 (21.97-26.57) 92 
Triceps skinfold thickness, mm 12.47 (9.61-16.78) 92 
Phase angle, ° 3.38 (2.61-4.34) 83† 
Extracellular fluid/intracellular fluid volume 0.91 (0.83-1.01) 89† 
Lean mass, kg 45.11 (36.20-52.74) 86† 
Fat mass, kg 19.97 (14.83-24.28) 86† 
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age ≥70 years; (iii) Overweight: 25≤BMI<30 if age <70 years and 27≤BMI<30 if age ≥70 years; 
(iv) Obese BMI≥30. 
* At time of diagnosis variation statistically different from 0 (p<0.0001). 
† Less than 92 due to impossible body impedance analysis or missing value 
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Medical care and outcome 
During follow-up, 39.10% of patients underwent non-invasive ventilation and 57.60% were 
gastrostomised. All patients were treated with riluzole. The proportion of gastrostomy was 
significantly higher in patients malnourished at the time of diagnosis (75.00%) as compared to 
patients with a normal BMI (59.50%), overweight patients (64.50%) and obese patients 
(18.20%), (p=0.036). Median time between diagnosis and gastrostomy placement was 10.00 
months (IQR 6.10-15.20). During follow-up, 74 patients died (80.40%), median survival time 
being 27.80 months, (95% confidence interval (95% CI), 19.50-30.40). 
 
Evolution of nutritional markers between diagnosis and death 
All nutritional markers varied between diagnosis and death (Table 1). Accordingly, weight, 
BMI, percentage of weight , BMI variation (as regards usual weight) and lean mass showed a 
significant worsening from diagnosis to death (Figures 1.a, 1.b, 1.c). Before death, median 
percent weight loss reached 7.05% (IQR 14.36-1.16) and median BMI loss 1.70 (3.62-.25). 
Fat-free mass also significantly decreased using bioimpedance (Figure 1.d) or mid-arm 
muscular circumference. Conversely, fat mass and triceps skinfold thickness significantly 
increased. Phase angle dramatically decreased (median value from 3.37° to 2.29°) and the 
ratio of extracellular fluid volume over intracellular fluid volume increased (median value 
from 0.93 to 1.00) (Figure 1.e). During follow up, the proportion of malnourished patients 
increased to 15.2%, though non-significantly (Mac Nemar Chi-square test p=0.058); the 
proportions of patients with normal BMI and who were overweight appeared stable (56.5% 
and 22.8%, respectively) and the proportion with obesity was reduced (5.5%). 
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Table 1: Nutritional variables at diagnosis and last evaluation for people who died during follow up 
Legend: IQR: Interquartile range. 
Nutritional variables 
At diagnosis Before death 
P value* N 
Median IQR Median IQR 
Weight, kg 65.60 (56.70-75.00) 63.10 (54.20-71.60) 0.02 74 
BMI 24.13 (21.20-26.96) 23.48 (20.86-26.60) 0.02 74 
Weight variation from usual weight (%) -2.29† (-8.40-0.50) -7.05 (-14.36- -1.16) 0.02 74 
BMI variation from usual BMI (unit) -0.53† (-2.24-0.10) -1.70 (-3.62- -0.25) 0.03 74 
Mid-arm muscle circumference, cm 23.89 (22.16-26.47) 22.02 (19.70-24.18) <0.0001 74 
Triceps skinfold thickness, mm 12.47 (9.30-16.30) 13.53 (9.92-19.33) 0.048 74 
Phase angle, ° 3.37 (2.57-4.34) 2.29 (1.69-2.97) <0.0001 66‡ 
Extracellular fluid/intracellular fluid volume 0.93 (0.84-1.02) 1.00 (0.90-1.11) <0.0001 72‡ 
Fat-free mass, kg 44.94 (36.20-52.74) 42.13 (33.99-48.65) <0.0001 69‡ 
Fat mass, kg 20.11 (14.10-24.28) 21.24 (14.50-28.36) 0.04 69‡ 
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* Comparisons between time of diagnosis and before death 
† At time of diagnosis variation statistically different from 0 (p<0.0001) 
‡ Less than 74 due to impossible body impedance analysis or missing values. 
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Prognostic value of nutritional markers at the time of diagnosis 
At the time of diagnosis, the percentage of weight lost from usual weight was significantly 
associated with survival. After adjustment for age, gender, bulbar form at onset, ALS FRS, 
MMT, FVC and diagnostic delay, we identified a 30% increase in the risk of death (95% CI 
8-56%) for each 5% decrease in weight (Table 2). We identified a significant difference in 
survival between ALS patients with a weight loss of 5% and over at the time of diagnosis 
(median survival time : 20.6 months (95% CI 12.4-29.0)) as compared to patients whose 
weight was stable or dropped by less than 5% (median survival time: 29.0 months (95% CI 
21.2-38.5)), Log rank test p=0.01, (Figure 2). Patients with a weight loss of 5% or over 
experienced an adjusted 1.92 Relative Risk (RR) of death (95% CI 1.15-3.18). Each BMI unit 
lost from the usual BMI was associated with an adjusted 20% increased risk of death (95% CI 
6-36%). Rate of weight loss (% per month) and rate of BMI loss (unit per month) between 
first symptoms and diagnosis were also independently associated with survival. Malnutrition 
at baseline and other nutritional variables including phase angle and ratio of extracellular fluid 
volume over intracellular fluid volume were not associated with survival in multivariate 
analysis. 
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Table 2: Relative risks of death associated with nutritional variables measured at diagnosis in univariate and multivariate analysis. Each 
nutritional variable has been analysed independently from other nutritional variables. 
Nutritional variables at diagnosis* 
Univariate analysis Multivariate analysis 
cHR 95% CI P value aHR† 95% CI P value 
Weight variationfrom usual weight (for 5% decrease) 1.28 1.06-1.54 0.009 1.31 1.08-1.60 0.006 
BMI variation from usual BMI (for one unit decrease) 1.20 1.06-1.36 0.005 1.23 1.07-1.41 0.003 
Rate of weight loss from usual weight (% / month) 1.09 1.04-1.14 0.0002 1.07 1.02-1.12 0.003 
Rate of BMI loss from usual BMI (unit / month) 1.35 1.16-1.58 0.0001 1.28 1.09-1.50 0.003 
Malnutrition at diagnosis vs other BMI categories 1.67 0.79-3.50 0.18 1.32 0.62-2.80 0.47 
Mid-arm muscle circumference, cm (for one unit increase) 0.96 0.90-1.03 0.23 0.95 0.89-1.01 0.12 
Triceps skinfold thickness, cm (for one unit increase) 0.99 0.96-1.03 0.81 1.00 0.96-1.03 0.78 
Phase angle, ° (for one unit decrease) 1.29 1.02-1.63 0.03 1.15 0.87-1.52 0.33 
Extracellular fluid/intracellular fluid volume (for 0.2 unit increase) 1.40 0.98-2.00 0.06 1.34 0.92-1.97 0.12 
Lean mass, kg (for 2.5 unit increase) 0.97 0.92-1.03 0.33 1.00 0.94-1.07 0.90 
Fat mass, kg (for 2.5 unit increase) 0.99 0.92-1.06 0.81 0.96 0.89-1.03 0.21 
Legend : cHR: crude Hazard Ratio; aHR: adjusted Hazard Ratio. 
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* Survival analyses were performed separately for each nutritional variable. 
† Adjustment on age, gender, bulbar form at onset, ALS FRS at diagnosis, manual muscular testing at diagnosis, forced vital capacity at 
diagnosis ≥80 vs <80, Airlie House criteria at diagnosis definite, probable or probable laboratory-supported vs possible and diagnostic delay. 
.
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Prognostic value of nutritional markers over the entire follow-up 
While considering nutritional status over the entire follow-up, we identified a 34% increased 
risk of death for each 5% decrease from usual weight and a 24% increased risk for each unit 
decrease from usual BMI (Table 3). Rate of weight loss during the course of the disease did 
not appear to be significantly associated with survival. Malnutrition also appeared 
significantly associated with survival (p=0.01). As compared to patients in the normal range 
of BMI, malnourished patients experienced a 2.15 (IC95% 1.09-4.25) increased risk of death, 
whereas overweight and obese patients tended to have reduced risk of death RR: 0.71 (IC95% 
0.40-1.28) and 0.36 (IC95% 0.11-1.19) respectively. An increase in fat mass using triceps 
skinfold thickness or bioimpedance was significantly associated with a better outcome. An 
increase in ratio of extracellular fluid volume over intracellular fluid volume was significantly 
associated with a shorter survival in multivariate analysis (p=0.02). In survival analyses there 
was no significant interaction between bulbar form at onset and BMI or weight loss at 
diagnosis or in subsequent follow-up.
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Table 3: Relative risks of death associated with nutritional variables measured over the entire follow-up in univariate and multivariate 
analysis. Each nutritional variable has been analysed independently from other nutritional variables. 
During follow-up nutritional variables* 
Univariate analysis Multivariate analysis 
cHR 95% CI P value aHR† 95% CI P value 
Weight variation from usual weight (for 5% decrease) 1.40 1.23-1.59 <0.0001 1.34 1.18-1.51 <0.0001 
BMI variation from usual BMI (for one unit decrease) 1.30 1.18-1.42 <0.0001 1.24 1.13-1.36 <0.0001 
Rate of weight loss from usual weight (% / month) 1.11 1.02-1.20 0.01 1.07 0.98-1.17 0.11 
Rate of BMI loss from usual BMI (unit / month) 1.44 1.08-1.93 0.01 1.28 0.94-1.74 0.11 
Malnutrition vs other BMI categories 2.32 1.25-4.29 0.007 2.56 1.33-4.94 0.005 
BMI categories   0.03   0.01 
 Malnutrition 2.15 1.14-4.08  2.15 1.09-4.25  
 Normality (reference) 1.00  
 
1.00   
 Overweight 0.98 0.56-1.72 
 
0.71 0.40-1.28  
 Obesity 0.43 0.13-1.40 
 
0.36 0.11-1.19  
Mid-arm muscle circumference, cm (for one unit increase) 0.89 0.82-0.95 0.001 0.93 0.86-1.005 0.07 
Triceps skinfold thickness, cm (for one unit increase) 0.99 0.96-1.03 0.66 0.94 0.90-0.98 0.003 
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Phase angle, ° (for one unit decrease) 1.68 1.27-2.23 0.0003 1.27 0.92-1.75 0.15 
Extracellular fluid/intracellular fluid volume (for 0.2 unit increase) 1.76 1.26-2.46 0.0009 1.67 1.07-2.61 0.02 
Lean mass, kg (for 2.5 unit increase) 0.94 0.89-1.002 0.06 1.00 0.94-1.07 0.97 
Fat mass, kg (for 2.5 unit increase) 0.98 0.91-1.04 0.46 0.90 0.83-0.96 0.003 
Legend : cHR: crude Hazard Ratio; aHR: adjusted Hazard Ratio; . BMI categorization: (i) Malnutrition: BMI <18.5 if age <70 years and 
BMI<21 if age ≥70 years; (ii) Normal status 18.5≤BMI<25 if age <70 years and 21≤BMI<27 if age ≥70 years; (iii) Overweight: 25≤BMI<30 if 
age <70 years and 27≤BMI<30 if age ≥70 years; (iv) Obesity BMI≥30. 
* Survival analyses were performed separately for each nutritional variable. 
† Adjustment on age, gender, bulbar form at onset, ALS FRS, manual muscular testing, forced vital capacity, Airlie House criteria during follow-
up and diagnostic delay. 
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DISCUSSION 
We have shown that patients with a weight loss from usual of 5% and over at the time of 
diagnosis experience a 2-fold increase in the risk of death (median survival time: 20.6 months 
(95% CI 12.4-29.0)) as compared to patients whose weight remains stable or drops by less 
than 5% (median survival time: 29.0 months (95% CI 21.2-38.5)). Weight loss at diagnosis 
was identified as an independent prognostic factor with an adjusted 30% increased risk of 
death for a 5% decrease from usual weight. We also identified during the course of ALS a 
decrease in weight, BMI, fat-free mass, and phase angle, and an increase in fat mass. We 
observed an adjusted 34% increased risk of death associated with each 5% decrease from 
usual weight during follow-up. Malnutrition during the course was associated with a shorter 
survival (p=0.01) and fat mass level was associated with a better outcome (RR 0.90 for each 
2.5-kg  fat mass increment). 
 
This work is, to our knowledge, the first demonstration of the prognostic value for survival of 
the nutritional status of ALS patients at time of diagnosis. Other authors have reported the 
prognostic significance of BMI for survival, but only if it is assessed at the time of 
gastrostomy placement (5), or an indication for non-invasive ventilation, (6) or during the 
course of the disease (14). A correlation analysis performed by Kasarskis et al. also found an 
association between BMI and proximity of death (15). 
 
Concerning malnutrition assessed by BMI during the follow-up, our results are in agreement 
with Desport et al. who, in 1999, (4) showed that malnutrition was an independent prognostic 
factor for survival. In that study, the mean delay between first symptoms and nutritional 
assessment (29±25 months) was longer than in our work where assessment was performed at 
time of diagnosis (median time between first symptoms and diagnosis 7.9 months (IQR 6.0-
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12.2)) and in subsequent follow-up. The absence of an association between malnutrition at 
diagnosis and survival here could be due to a lack of power caused by the low initial 
percentage (8.7%) of malnourished patients. 
 
In a seminal paper, Slowie et al. reported that for a limited number of ALS patients during a 
large range of times between diagnosis and assessment (6 months to 11 years) 25% of patients 
lost 10% of their weight (1). According to our data, at time of diagnosis, the nutritional status 
of patients is already highly altered: 50% lost more than 2.3% of weight and 25% lost more 
than 7.8% and 2 units of BMI. It has to be acknowledged that alteration of nutritional status is 
multifactorial: progressive muscular wasting due to denervation (1), swallowing or salivary 
disorders and dysphagia present at the time of diagnosis in patients with the bulbar form or 
appearing during the course are also implicated (4). In addition, anorexia, digestive disorders 
and upper limb motor difficulties contribute to low intake. Moreover, an increase in energy 
requirement sufficient to exceed intake has been demonstrated in 50% of patients (2-3). The 
reason for this hypermetabolism is not known. Our study was not designed to explore the 
respective contributions of these factors. A further study looking at that point could also 
assess the link between mobility and the weight/body composition of ALS patients. 
Following the literature, only 9% of patients were malnourished according to BMI at the time 
of diagnosis, reaching 15% at the last nutritional evaluation (4, 16, 17). This alteration is also 
highlighted by the dramatic reduction in phase angle at time of diagnosis and before death. 
The early decrease of phase angle during ALS reflects alteration of the body composition, and 
general health and function. Similar patterns are displayed by the ratio of extracellular fluid 
volume over intracellular fluid volume. 
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In common with Nau et al (18) and other authors (19), we identified modifications of body 
compartments in ALS patients, with a loss of fat-free mass and a gain of fat mass during the 
course. Our study shows for the first time that a higher fat mass is beneficial for survival of 
ALS patients. Similar results have already been  reported in chronic obstructive pulmonary 
disease (20), cardiac insufficiency (21), and in hemodialysis patients (22) suggesting that in 
several chronic diseases a moderate excess of weight could aid survival. In ALS patients, 
Dupuis et al. (7) have shown that patients with high LDL/HDL cholesterol have longer 
survival confirming previous results in mice (23). It is worth considering whether high 
LDL/HDL may be associated in many cases with either a sustained nutritional status or a 
weight excess with higher fat storage. In accord with Patel et al. (24), our results suggest that 
enhanced fat storage through an energy enriched diet may improve patient survival. This 
hypothesis is also supported by animal models showing better outcome for SOD1-G93A 
transgenic ALS mice fed with a ketogenic diet (25). This concept is opposed to previous 
suggestions that modest weight loss may be desirable early in the course of the disease in 
order to obviate unnecessary accumulation of fat (26). 
 
We have to acknowledge that usual predictions from hospital-based study may have limited 
validity for population-based patients. Rapidly deteriorating patients may not survive until 
referral to an academic centre or may be too ill to go there whereas younger patients are more 
likely to seek a second opinion. Although our study is hospital-based, our ALS centre is the 
only multidisciplinary care centre in our region and our incidence profile (2.0/100 000 
inhabitants for the 1997-2007 period and 4.4/100 000 in the 45-74 age group) is highly 
consistent with data from American or European registries (27). It can be convincingly argued 
that our centre is representative of the ALS population. Moreover, due to the inclusion criteria 
(follow-up by our nutrition unit), half the patients had a bulbar form at onset. We think our 
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results provide valuable information relevant to the whole ALS population because our study 
population is probably better followed from a nutritional point of view than the ALS 
population overall. 
 
This result has three main implications. First, our findings provide important support for a 
reevaluation of daily routine nutritional management and for considering early nutritional 
intervention to improve survival of ALS patients. The prognostic value of weight loss at the 
time of diagnosis and quite late nutritional interventions allow us to propose close monitoring 
of nutritional status following a diagnosis of ALS. Despite the value of BIA in monitoring 
body composition, our results and their clinical application support weight assessment as the 
first priority. We propose a weight loss of 5% from usual be considered a threshold for 
systematic dietary recall, nutritional assessment, and BIA evaluation of fat mass and fat-free 
mass. For people without such a weight loss, close monitoring every 3 months of weight at 
least could be appropriate.  
 
Our results have other implications for epidemiological and clinical research. Weight loss at 
the time of diagnosis is an independent prognostic factor for survival of ALS patients, 
therefore observational studies should adjust their estimations accordingly. Those conducting 
clinical trials might use percentage weight loss as a stratification criterion because a slight 
disequilibrium between groups for this strong prognostic factor could mask the modest 
efficacy of a new treatment. 
 
Finally, in contrast to other recognised prognostic factors at diagnosis, the nutritional status of 
patients can be modified using oral or enteral procedures. It is interesting to consider that the 
correction of weight loss at diagnosis could exceed the effect of riluzole on survival (28). 
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Consequently, trials to investigate such interventions are needed. Early enteral nutrition could 
be a challenge because studies showed that percutaneous endoscopic gastrostomy (PEG) is 
effective in stabilizing body weight/BMI. According to the American guidelines for 
management of ALS patients, there is level B evidence that PEG should be considered for 
prolonging survival in patients with ALS, but the optimum time for PEG insertion is still 
unknown (29). There is however growing evidence that PEG placement should be performed 
before FCV<50% to prevent respiratory deficiency during insertion, and radiological inserted 
gastrostomy has been shown to be a safe alternative below this threshold (30). Although 
European guidelines for care of ALS patients state that PEG placement should be envisaged 
early in the course of the disease (31), patients have difficulty accepting it then. The median 
delay between diagnosis and gastrostomy placement in our study (10 months) can be 
considered as early, but is probably late as far as nutritional status and improvement of 
survival are concerned. Another trial could investigate the effects of nutritional 
supplementation enriched in energy and lipids close to diagnosis as compared with a diet 
adapted for caloric needs. 
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